2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
3
Active Trials
200 recruiting
2
Rare Diseases
across 4 areas
0
News (30d)
Quiet
Imunon, Inc. is a company with 2 orphan drug designations across 2 rare diseases. Active clinical trials in 3 indications.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| hepatocellular carcinoma | lyso-thermosensitive lipsomal doxorubicin | Des.TrialAppr. |
| ovarian cancer | DNA plasmid vector expressing human IL-12 gene | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
13
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
13
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio